Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-20-009776
Date:2020-03-30
Issuer: MYOVANT SCIENCES LTD. (MYOV)
Original Submission Date:

Reporting Person:

SUMITOMO CHEMICAL CO., LTD.
27-1, SHINKAWA 2-CHOME
CHUO-KU, TOKYO, M0 104-8260

Reporting Person:

DAINIPPON SUMITOMO PHARMA CO LTD
6-8 DOSHOMACHI 2-CHOME
CHUO-KU, OSAKA, M0 541-0045

Reporting Person:

SUMITOVANT BIOPHARMA LTD.
11-12 ST. JAMES'S SQUARE SUITE 1
3RD FLOOR LONDON, X0 SW1Y 4LB

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-03-30 P 70,000 a $7.65 46,718,604 indirect f3
COMMON STOCK 2020-03-31 P 70,000 a $7.97 46,788,604 indirect f5
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 this acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a rule 10b5-1 stock trading plan entered into by the reporting person on march 13, 2020 (the "10b5-1 trading plan").
f2 the price reported in column 4 is the average stock price.
f3 sumitovant biopharma ltd. ("sumitovant") directly owns 46,718,604 shares of common stock. sumitovant is a wholly-owned subsidiary of sumitomo dainippon pharma co., ltd. ("sumitomo dainippon"), which is a 51.76% owned subsidiary of sumitomo chemical co., ltd. ("sumitomo chemical"). sumitomo dainippon and sumitomo chemical may be deemed to indirectly beneficially own (as that term is defined in rule 13d-3 under the securities exchange act of 1934, as amended) the reported securities that sumitovant owns. each of sumitomo dainippon and sumitomo chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
f4 this acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 trading plan.
f5 sumitovant directly owns 46,788,604 shares of common stock. sumitovant is a wholly-owned subsidiary of sumitomo dainippon, which is a 51.76% owned subsidiary of sumitomo chemical. sumitomo dainippon and sumitomo chemical may be deemed to indirectly beneficially own (as that term is defined in rule 13d-3 under the securities exchange act of 1934, as amended) the reported securities that sumitovant owns. each of sumitomo dainippon and sumitomo chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
WhaleWisdom Logo

Elevate your investments